What Supracef (Cefixime) Treats: Main Uses and Benefits

Cefixime is commonly used to help manage bacterial infections across several therapeutic contexts.

The medication is relevant for addressing symptoms related to inflammatory or irritative states in the ear and respiratory tract, in conditions such as throat inflammation, sinus issues, and acute flare-ups of chronic bronchitis. It also applies to specific uncomplicated conditions presenting with localized discomfort, such as urinary tract infections (UTIs) and Otitis Media (ear infection). Cefixime is also applied in contexts involving heightened systemic burden, relevant for certain conditions where symptoms may intensify temporarily.

The therapeutic benefit is that the medication helps address symptom clusters that may become intense, such as fever, sore throat, and pronounced ear pain. It is often used in an outpatient setting when short-term symptomatic assistance is needed.

“The primary goal of Cefixime use is to provide supportive relief during acute bacterial episodes, assisting with maintaining functional stability.”

Quick Fact: Managing Painful Urination (Dysuria) Cefixime is commonly used to help manage symptoms of uncomplicated UTIs, providing support that assists with maintaining functional stability and easing the distress of frequent, painful voiding.

The use of this medication assists with maintaining functional stability and coping more steadily with symptom fluctuations that interfere with daily functioning.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility and Contraindications for Supracef (Cefixime)

Official regulatory information defines specific populations that are eligible, restricted, or prohibited from using Cefixime.

Absolute Non-Eligibility (Contraindications)

Classification	Rule	Basis
Allergy	Prohibited for patients with known hypersensitivity to Cefixime, any other cephalosporin antibiotic, or a history of severe allergic reaction to any beta-lactam antibiotic (e.g., penicillins) due to cross-reactivity risk.

Age-Group Eligibility

Cefixime is approved for use in adults and pediatric patients aged six months and older. Safety and effectiveness have not been established in infants younger than six months. Older adults may use the standard adult dose, but their renal function should be assessed.

Conditional Use Requirements

• Renal Function: Use is conditional in patients with impaired renal function. A dose adjustment is required when the Creatinine Clearance (CrCL) is less than 60 mL/min. Use in pediatric patients with renal insufficiency is generally not recommended due to limited data.
• Reproductive Status: In pregnant and breastfeeding women, Cefixime should be used only if clearly needed. Consideration should be given to temporarily discontinuing nursing during treatment.

Interactions with other medicines and products

Supracef (Cefixime) has documented interaction patterns primarily involving pharmacodynamic reinforcement and altered drug exposure according to official regulatory labeling. No drug-drug combinations are formally classified as contraindicated in major regulatory documents.

Interacting Substance/Class	Official Interaction Outcome
Warfarin and Anticoagulants (Coumarin-type)	Increased prothrombin time (PT) has been reported, with or without clinical bleeding, indicating an enhanced effect of the anticoagulant.
Carbamazepine	Reports indicate elevated Carbamazepine plasma concentrations when co-administered with Cefixime. Monitoring drug levels may be advised.
Probenecid	Co-administration increases Cefixime peak serum concentration (Cmax) and AUC by decreasing its renal clearance.
Oral Contraceptives	Use of Cefixime may reduce the effectiveness of hormonal oral contraceptives.

Official prescribing information notes that certain populations, including those with renal impairment, a poor nutritional state, or those on protracted antimicrobial therapy, may be at increased risk of a fall in prothrombin activity when taking anticoagulants. Furthermore, Cefixime may cause false-positive results for urinary glucose tests (using copper sulfate methods) and the direct Coombs test.

How Supracef (Cefixime) Works

The action of Cefixime is bactericidal, meaning it causes the destruction of susceptible bacterial cells by interfering with their structural integrity. The mechanism is highly targeted, focused exclusively on the bacterial cell wall assembly process.

Inhibition of Bacterial Cell Wall Synthesis

Cefixime functions as an irreversible inhibitor of essential bacterial enzymes called Penicillin-Binding Proteins (PBPs), primarily targeting PBP 3. These enzymes are responsible for the transpeptidation (cross-linking) step, which is vital for building the structural network of the peptidoglycan layer of the cell wall. By covalently binding to and disabling the PBPs, the drug halts the construction process.

Lytic Cascade and Pathogen Destruction

The failure of the cell wall to properly form causes a rapid loss of osmotic stability. The high internal pressure (turgor) of the bacterial cell can no longer be contained by the weakened structure, triggering a fatal lytic cascade. This systemic breakdown results in cell membrane rupturing and cell lysis. This mechanistic cascade leads to the bactericidal effect.

Intrinsic beta-Lactamase Stability

A feature of this third-generation cephalosporin is its stability against hydrolysis by many common beta-lactamase enzymes. These bacterial defense enzymes typically inactivate beta-lactam antibiotics. By resisting this enzymatic destruction, Cefixime maintains its binding capacity to the PBPs, allowing the core PBP-inhibition mechanism to proceed in the presence of those enzymes.

Official Administration Guidelines

Cefixime administration follows specific guidelines concerning dose, route, and duration.

---

Administration Scope and Dosing

Category	Official Administration Guideline
Route of administration	Oral only; no injectable forms are approved for systemic use.
Standard Adult Dosing	400 mg daily, which may be administered as a single dose or divided into 200 mg every 12 hours.
Timing in relation to meals	May be taken without regard to food

---

The standard adult daily dose is 400 mg, which provides flexibility in scheduling as a once- or twice-daily regimen. For specific acute infections, a single 400 mg dose is used. The medication is available as tablets, capsules, and an oral suspension, with the suspension form requiring reconstitution and shaking before measurement.

Population-Specific Rules and Constraints

Procedural rules are established for patient safety and efficacy. For adults with renal impairment, a dose adjustment is required when creatinine clearance (CrCl) falls below 60 mL/min. For severe impairment (CrCl le 20 mL/min), the dose must generally not exceed 200 mg once daily. Cefixime is not established for children younger than 6 months.

The treatment course must be followed for the full prescribed duration, with a minimum of 10 days required for infections caused by Streptococcus pyogenes. If a dose is missed, the standard procedure is to take it as soon as remembered, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped to avoid double dosing.

Supracef (Cefixime): Recent Clinical Evidence

Overview of Studies

Cefixime is classified as a third-generation cephalosporin antibiotic. Clinical research on this compound focuses primarily on its use against various bacterial infections, including those affecting the ears, throat, urinary tract, and lower respiratory system.

Early Research and Mechanism

Early research focused on how the compound interacts with biological processes. Studies examined whether the compound affects inflammatory pathways. Cefixime works by interfering with the synthesis of the bacterial cell wall, which is essential for bacterial survival. It is effective against both Gram-negative and Gram-positive organisms.

Research has also evaluated how the drug is absorbed and metabolized. The oral bioavailability of Cefixime is approximately 40% to 50%, with absorption potentially slowed but not decreased when taken with food.

---

Key Clinical Trial Outcomes

Numerous placebo-controlled trials have been conducted to evaluate the compound’s effects across various conditions. These trials track outcomes like symptom resolution, microbiological clearance, and tolerability.

• Respiratory Infections (e.g., Tonsillitis, Pharyngitis): Studies have investigated the effectiveness of shorter-course therapy with Cefixime compared to longer courses of older antibiotics. Findings from some comparative trials suggest similar outcomes in bacterial eradication rates, though symptom resolution may occur faster in the Cefixime group.
• Uncomplicated Urinary Tract Infections (UTIs): Cefixime has been assessed as a treatment option for UTIs caused by susceptible strains. Research often compares its efficacy against other standard treatments, particularly in regions with rising antibiotic resistance.

Safety and Long-Term Data

Long-term studies focus on tracking participant outcomes over extended periods and recording safety data. Reported events did not lead to participant withdrawal in the study, though the most commonly reported events are gastrointestinal disturbances and headaches. Safety measures and adverse event reporting were integral to the clinical trials.

Common questions about Supracef (Cefixime) (FAQ)

---

Q: What specific types of infections does Cefixime treat?

Official prescribing information states that Cefixime is approved for treating specific infections caused by susceptible bacteria. These include uncomplicated urinary tract infections, otitis media (ear infection), pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea.

---

Q: Does Supracef interact with commonly used pain relievers?

Regulatory documents list known interactions with certain prescription medicines like carbamazepine, but they do not generally contain warnings for common non-prescription pain relievers. If you are taking any other drug, including over-the-counter pain relievers, this type of information should be discussed with a healthcare professional.

---

Q: Is there a difference in how the tablet and the liquid suspension forms of Cefixime work?

Studies reviewed by regulatory bodies indicate that the tablet and the oral suspension forms are not bioequivalent, meaning the body absorbs and processes them differently. The suspension formulation typically results in higher peak concentrations in the blood than the tablets. Prescribers take this difference into account when deciding which formulation is most appropriate for a patient.

---

Q: How long does a course of Supracef typically last?

The total duration of treatment varies depending on the type of infection being treated. Official guidelines specifically state that for infections caused by the bacteria Streptococcus pyogenes (such as a strep throat infection), the course of medicine is specified as a minimum of 10 days.

---

Q: Why is Cefixime sometimes chosen by doctors over other antibiotics for certain infections?

Cefixime is classified as a third-generation cephalosporin, and this class of antibiotics is known for its stability against certain bacterial defense enzymes called beta-lactamases. This characteristic means the drug maintains its action against some bacteria that have developed resistance to older antibiotics. Official information notes the drug is effective at eradicating the bacteria that cause strep throat.

---

Q: What is known about the development of bacterial resistance to Cefixime?

Official prescribing information states that using Cefixime when a bacterial infection has not been proven is associated with a potential for the development of drug-resistant bacteria. The regulatory label also notes that most bacteria of the staphylococci class are generally resistant to Cefixime.

---

Q: What information is available regarding Supracef's use for ear infections (otitis media)?

Regulatory documents indicate that Cefixime is approved for treating otitis media (ear infections) in patients six months of age or older. It is specifically indicated for infections caused by susceptible strains of certain bacteria, including Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.

---

Q: Is it normal to feel tired while taking Supracef?

While tiredness is not listed as a common side effect in official reports, adverse event reports from clinical trials include central nervous system effects like dizziness. Unusual weakness or tiredness is included in the list of symptoms that may be associated with serious, though rare, blood or liver system effects noted in official documentation.

---

Q: Why does Cefixime sometimes cause changes in appetite?

Clinical trial data reviewed in the official product information lists loss of appetite as a potential side effect. This is categorized under gastrointestinal adverse reactions, which were the most commonly reported events during studies of the tablet formulation.

---

Q: Can I consume alcohol while taking Supracef?

The regulatory drug label for Cefixime does not contain a specific warning about an interaction with alcohol. However, Consultation with a healthcare professional regarding lifestyle factors, including alcohol consumption, is generally advisable before beginning any new medication.

---

Q: Are there any specific foods that should be avoided when taking Cefixime?

Official prescribing information explicitly states that Cefixime tablets and capsules may be administered without regard to food. This means that there are no specific food restrictions mentioned in the regulatory guidelines for proper use of the medication.

---

Q: What should a patient know if they accidentally take too much Cefixime?

Official information directs individuals to seek emergency medical attention in the event of an overdose. Official information indicates that high doses or improper dosing, particularly in people with impaired kidney function, may potentially result in serious effects, including seizures.

---

Q: Has the drug's effectiveness been studied in elderly populations?

Official prescribing information notes a limitation in the original clinical trials: they did not include a sufficient number of subjects aged 65 and older to definitively determine if their response differed from younger patients. However, subsequent clinical experience has not identified differences in response between the elderly and younger patient groups.

---

Q: What percentage of people report experiencing headache while taking Cefixime?

Headache is listed as an adverse reaction in the official product information. In U.S. clinical trials of the tablet formulation, headache was reported in less than 1 in 50 patients, which corresponds to an incidence rate of under 2%.

Storage and Disposal of Cefixime (Supracef)

The official storage conditions for Cefixime depend on the dosage form.

• Tablets, Capsules, and Dry Powder: These forms must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture and should be kept in the original, tightly closed container.

• Reconstituted Oral Suspension: The liquid suspension may be kept at room temperature or refrigerated, but it must be discarded after 14 days from the date of preparation.

Handling Requirement	Official Mandate
Child Safety	Store out of the sight and reach of children.
Disposal	Dispose of unused or expired product according to official local regulations.